Financial Contrast: Glaukos Corporation (GKOS) versus Cerus Corporation (CERS)
Glaukos Corporation (NYSE: GKOS) and Cerus Corporation (NASDAQ:CERS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.
Valuation & Earnings
This table compares Glaukos Corporation and Cerus Corporation’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Glaukos Corporation||$139.94 million||10.33||$8.15 million||($0.05)||-840.00|
|Cerus Corporation||$36.83 million||7.94||-$61.75 million||($0.61)||-4.39|
Glaukos Corporation has higher revenue and earnings than Cerus Corporation. Glaukos Corporation is trading at a lower price-to-earnings ratio than Cerus Corporation, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Glaukos Corporation has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Cerus Corporation has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500.
Insider & Institutional Ownership
58.7% of Cerus Corporation shares are owned by institutional investors. 16.4% of Glaukos Corporation shares are owned by insiders. Comparatively, 7.4% of Cerus Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Glaukos Corporation and Cerus Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Glaukos Corporation and Cerus Corporation, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Glaukos Corporation currently has a consensus price target of $54.60, indicating a potential upside of 30.00%. Cerus Corporation has a consensus price target of $7.25, indicating a potential upside of 170.52%. Given Cerus Corporation’s higher possible upside, analysts clearly believe Cerus Corporation is more favorable than Glaukos Corporation.
Glaukos Corporation beats Cerus Corporation on 9 of the 12 factors compared between the two stocks.
Glaukos Corporation Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Cerus Corporation Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.